Andrew Hall

Form D signer

Andrew Hall

Chief Executive Officer of Issuer at Consano Bio

Form D signer

Capital raised by Consano Bio

$51.7M+$34.8M latest round

2 Form D filings · first filed Oct 2024 · Burlington, MA

CURRENT ROLE: Chief Executive Officer of Issuer
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 3
FOUNDED: 2022
30D INTEREST: 1 ↗

Career

1 company on file · founded 2022

Consano BioBiotech · Burlington, MAsince 2022

Chief Executive Officer of Issuer

Signatory on Consano Bio's Form D filings · $51.7M raised across 2

Company filings

via EDGAR · Form D for Consano Bio2

DateCompanyFormAmountRole on filing

Mar 6, 2026Consano BioForm D+$34.8MChief Executive Officer of Issuer

Form DMar 6, 2026 · Consano Bio+$34.8Mas Chief Executive Officer of Issuer

Oct 15, 2024Consano BioForm D+$16.8MChief Executive Officer of Issuer

Form DOct 15, 2024 · Consano Bio+$16.8Mas Chief Executive Officer of Issuer

Overview

Last filing Mar 6, 2026

Andrew Hall is on file as Chief Executive Officer of Issuer at Consano Bio in Burlington, MA. Consano Bio has 2 Form D filings on record, $51.7M raised in total. Andrew Hall appears as a signatory on the company's filings.

Teammates

Consano Bio · 2

Jerome AdamsDirector John ConwayDirector

Products

Consano Bio · 1

C-1101Biologic Therapeutic

C-1101 is an allogenic, multi-protein therapeutic currently in development. It is engineered to treat orthopedic injuries by modulating the local environment to favor healing and tissue regeneration.